Neptune Technologies & Bioressources Inc. J (T:NTB)
Business Focus: N/A
Nov 13, 2017 05:30 pm ET
Acasti Pharma Reports Second Quarter FY 2018 Financial Results
Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced its operating and financial results for the quarter ended September 30, 2017, which is the second quarter of Acasti's fiscal year 2018. All amounts are in Canadian dollars.
Nov 13, 2017 05:28 pm ET
Acasti Pharma Reports Second Quarter FY 2018 Financial Results
Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe...
Nov 07, 2017 05:00 pm ET
Acasti Pharma Announces Dariush Mozaffarian, M.D., Dr.P.H. Principal Investigator for CaPre Phase 3 Development Program
Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that Dariush Mozaffarian, M.D., Dr.P.H. has agreed to serve as Acasti's principal investigator to oversee the Phase 3 development program of CaPre. Dr. Mozaffarian is a renowned researcher whose widely published work focuses on how diets such as those rich in omega-3s and lifestyle can influence cardiometabolic health.
Nov 07, 2017 04:58 pm ET
Acasti Pharma Announces Dariush Mozaffarian, M.D., Dr.P.H. Principal Investigator for CaPre Phase 3 Development Program
Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe...
Aug 16, 2017 11:52 pm ET
Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock Option Plan and Other Related Matters Approved at Its AGM
Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced that the...
Aug 16, 2017 11:52 pm ET
Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock Option Plan and Other Related Matters Approved at Its AGM
Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced that the following individuals were elected as directors of Acasti Pharma Inc. ("Acasti" or the "Corporation") at its Annual and Special Meeting of Shareholders, held in Montreal, Canada on August 15, 2017 (the "AGM"): Janelle D'Alvise, Jean-Marie (John) Canan, Roderick N. Carter, Richard P. Schottenfeld and Katherine Crewe.
Jun 06, 2017 04:30 pm ET
Acasti Pharma Reports Fourth Quarter and Full-Year 2017 Financial Results
Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST) today announced its operating and financial results for the fiscal year ended March 31, 2017. The company announced on July 15, 2016 that it would transition to a new fiscal year-end in 2017 to better align Acasti with industry comparables and standard quarters. Accordingly, Acasti's fiscal year ended on March 31, 2017 rather than on February 28, 2017. For the purpose of its regulatory filings, Acasti is reporting results for the thirteen-month transition period ended March 31, 2017, reflecting its fourth quarter period covering the four
Jun 06, 2017 04:28 pm ET
Acasti Pharma Reports Fourth Quarter and Full-Year 2017 Financial Results
Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST) today announced its operating and financial results for the fiscal year ended March 31, 2017. The company announced on July 15, 2016 that it would transition to a new fiscal year-end in 2017 to...
Feb 24, 2017 12:33 pm ET
Acasti Pharma Grants Incentive Stock and Options
Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ: ACST)(TSX VENTURE: ACST), today announced the grant of an aggregate of 100,000 incentive stock options under the Corporation's Stock Option Plan for two new independent directors who joined Acasti's Board of Directors at the last Annual and Special Meeting of Shareholders, held in July 2016. Each option will vest over a period of 30 months and will entitle its holder to purchase one common share of Acasti at a price of CDN $1.65, until February 24, 2027.
Feb 24, 2017 12:33 pm ET
Acasti Pharma Grants Incentive Stock and Options
Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ:ACST)(TSX VENTURE:ACST), today announced the grant of an aggregate of 100,000 incentive stock options under the Corporation's Stock Option Plan for two new independent directors who...
Feb 10, 2017 04:26 pm ET
Acasti Pharma Announces Pricing for its Public Offering of Units
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
February 10, 2017 - Acasti Pharma Inc. ("Acasti", "Acasti Pharma" or the "Corporation") (NASDAQ:ACST)(TSX VENTURE:ACST) today announced that it has...
Feb 02, 2017 11:33 am ET
Acasti Pharma Announces Proposed Private Placement of Convertible Debentures and Amended Proposed Offering of Units
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Acasti Pharma Inc. ("Acasti", "Acasti Pharma" or the "Corporation") (NASDAQ:ACST)(TSX VENTURE:ACST) today announced that it entered into a...
Feb 02, 2017 11:33 am ET
Acasti Pharma Announces Proposed Private Placement of Convertible Debentures and Amended Proposed Offering of Units
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Jan 12, 2017 05:15 pm ET
Acasti Pharma Reports Third Quarter 2017 Financial Results
Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ: ACST)(TSX VENTURE: ACST) today announced its operating and financial results for the third quarter of its 2017 fiscal year, which ended November 30, 2016. All amounts are in Canadian dollars.
Jan 12, 2017 05:13 pm ET
Acasti Pharma Reports Third Quarter 2017 Financial Results
Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ:ACST)(TSX VENTURE:ACST) today announced its operating and financial results for the third quarter of its 2017 fiscal year, which ended November 30, 2016. All amounts are in Canadian...
Dec 05, 2016 05:37 pm ET
Acasti Pharma Announces Proposed Offering of Units
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Acasti Pharma Inc. ("Acasti", "Acasti Pharma" or the "Corporation") (NASDAQ:ACST)(TSX VENTURE:ACST) today announced that it has received a receipt for...
Nov 07, 2016 08:00 am ET
Validity of Neptune's Patent Upheld by Australian Patent Office
Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT)(TSX: NTB), today announced that the Australian Patent Office has confirmed the validity of all 97 claims under Neptune's Australian composition of matter patent (AU 2002322233) (the "Neptune claims"). As a result, Neptune has overcome Enzymotec Ltd. and Enzymotec USA, Inc.'s (together, "Enzymotec") third attempt to invalidate any of the Neptune claims.
Nov 07, 2016 07:58 am ET
Validity of Neptune's Patent Upheld by Australian Patent Office
Neptune Technologies & Bioressources Inc. (NASDAQ:NEPT)(TSX:NTB), today announced that the Australian Patent Office has confirmed the validity of all 97 claims under Neptune's Australian composition of matter patent (AU 2002322233) (the "Neptune...
Nov 04, 2016 08:00 am ET
Neptune Announces Stock Ticker Symbol Change to NEPT on the TSX
Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT)(TSX: NTB), today announced that as a result of the recent recent introduction of four-letter root symbols on Toronto Stock Exchange ("TSX"), the company applied and received authorization to change its stock ticker symbol to "NEPT" (TSX.NEPT) on TSX, effective November 8, 2016.
Nov 04, 2016 07:58 am ET
Neptune Announces Stock Ticker Symbol Change to NEPT on the TSX
Neptune Technologies & Bioressources Inc. (NASDAQ:NEPT)(TSX:NTB), today announced that as a result of the recent recent introduction of four-letter root symbols on Toronto Stock Exchange ("TSX"), the company applied and received...
Nov 03, 2016 08:00 am ET
Acasti Announces Stock Ticker Symbol Change to ACST on the TSXV
Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: APO), today announced that as a result of the recent introduction of four-letter root symbols on the TSX Venture Exchange (TSXV), the company applied and received authorization to change its stock ticker symbol to "ACST" (TSX VENTURE: ACST) on TSXV, effective November 8, 2016.
Nov 03, 2016 07:58 am ET
Acasti Announces Stock Ticker Symbol Change to ACST on the TSXV
Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:APO), today announced that as a result of the recent introduction of four-letter root symbols on the TSX Venture Exchange (TSXV), the company applied and received authorization to change its stock ticker...
Oct 26, 2016 08:00 am ET
Acasti Pharma Builds Intellectual Property Portfolio with Newly Issued U.S. Patent for CaPre
Acasti Pharma (NASDAQ: ACST)(TSX VENTURE: APO) today announced that the United States Patent and Trademark Office issued Acasti a patent (U.S. patent no. 9,475,830) directed to a method of treating hypertriglyceridemia by the administration of a concentrated phospholipid composition.
Oct 26, 2016 07:58 am ET
Acasti Pharma Builds Intellectual Property Portfolio with Newly Issued U.S. Patent for CaPre
Acasti Pharma (NASDAQ:ACST)(TSX VENTURE:APO) today announced that the United States Patent and Trademark Office issued Acasti a patent (U.S. patent no. 9,475,830) directed to a method of treating hypertriglyceridemia by the administration...
Oct 12, 2016 04:00 pm ET
Neptune Announces Second Quarter Results
Financial and Operational Highlights(1):
Oct 12, 2016 03:58 pm ET
Neptune Announces Second Quarter Results
Financial and Operational Highlights1:
Revenues reached $11.6 million, up 165% versus last year
Gross margin on sales rose to 20.4% compared to 14% last year
Neptune will receive net US$6...
Oct 11, 2016 05:00 pm ET
Acasti Pharma Reports Second Quarter 2017 Financial Results
Acasti Pharma (NASDAQ: ACST)(TSX VENTURE: APO) today announced its operating and financial results for the second quarter of its 2017 fiscal year, which ended August 31, 2016. All amounts are in Canadian dollars.
Oct 11, 2016 04:58 pm ET
Acasti Pharma Reports Second Quarter 2017 Financial Results
Acasti Pharma (NASDAQ:ACST)(TSX VENTURE:APO) today announced its operating and financial results for the second quarter of its 2017 fiscal year, which ended August 31, 2016. All amounts are in Canadian dollars.
"During our second fiscal...
Oct 07, 2016 08:06 am ET
Neptune and Ingenutra Sign an Exclusive Worldwide Agreement for MaxSimil®
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ:NEPT)(TSX:NTB) through its wholly-owned subsidiary, Biodroga Nutraceutical Inc., has signed an exclusive, worldwide and royalty bearing commercial agreement with...
Oct 07, 2016 08:06 am ET
Neptune and Ingenutra Sign an Exclusive Worldwide Agreement for MaxSimil®
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ: NEPT)(TSX: NTB) through its wholly-owned subsidiary, Biodroga Nutraceutical Inc., has signed an exclusive, worldwide and royalty bearing commercial agreement with Ingenutra Inc. for its patented and clinically studied MaxSimil specialty ingredient. Designed as a unique delivery system, MaxSimil allows for enhanced bioavailability and absorption of lipid based and lipid soluble nutraceuticals ingredients such as omega-3 fish oils, vitamin A, D, K and E, CoQ10 and others.
Oct 03, 2016 08:20 am ET
Neptune and Aker BioMarine Reach Important Patent Agreement, Recognizing the Patents' Strength and Ending All Litigation
Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ: NEPT)(TSX: NTB) and Aker BioMarine ("Aker") are pleased to jointly announce that they have entered into a broad patent cross-licensing agreement, thus ending all outstanding litigation between both companies.
Oct 03, 2016 08:20 am ET
Neptune and Aker BioMarine Reach Important Patent Agreement, Recognizing the Patents' Strength and Ending All Litigation
Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ:NEPT)(TSX:NTB) and Aker BioMarine ("Aker") are pleased to jointly announce that they have entered into a broad patent cross-licensing agreement, thus ending all outstanding litigation...
Sep 28, 2016 10:50 am ET
Neptune to Hold Conference Call to Discuss Second Quarter Results for the Period Ended August 31, 2016
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ:NEPT)(TSX:NTB), announces that it will be holding a conference call on October 12, 2016 at 5:00 PM (EST) to discuss its second quarter results for the period ended...
Sep 28, 2016 10:50 am ET
Neptune to Hold Conference Call to Discuss Second Quarter Results for the Period Ended August 31, 2016
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ: NEPT)(TSX: NTB), announces that it will be holding a conference call on October 12, 2016 at 5:00 PM (EST) to discuss its second quarter results for the period ended August 31, 2016.
Sep 15, 2016 04:30 pm ET
NEPTUNE Introduces NKO(R) Omega Plus, a New and Innovative Krill Oil Product with one of the Highest Concentration of Omega-3s
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (NASDAQ: NEPT)(TSX: NTB), today announced that NKO(R) Omega Plus will now be one of the highest omega-3 concentration of pure krill oil product available on the market. Neptune's proprietary extraction process enables NKO(R) Omega Plus to contain up to 30% more Omega-3 than krill oil products typically on the market today.
Sep 15, 2016 04:29 pm ET
NEPTUNE Introduces NKO(R) Omega Plus, a New and Innovative Krill Oil Product with one of the Highest Concentration of Omega-3s
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (NASDAQ:NEPT)(TSX:NTB), today announced that NKO® Omega Plus will now be one of the highest omega-3 concentration of pure krill oil product available on the market....
Sep 14, 2016 08:00 am ET
Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data
Acasti Pharma (NASDAQ: ACST)(TSX VENTURE: APO) today announced that its bridging study for novel drug candidate CaPre(R) (omega-3 phospholipid) has successfully met its objectives, supporting Acasti's strategy to pursue the U.S. Food and Drug Administration's (FDA) 505(b)(2) regulatory pathway for approval. Acasti is developing CaPre for the treatment of patients with severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis. The 505(b)(2) regulatory pathway allows Acasti to streamline the overall development program
Sep 14, 2016 07:58 am ET
Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data
Acasti Pharma (NASDAQ:ACST)(TSX VENTURE:APO) today announced that its bridging study for novel drug candidate CaPre® (omega-3 phospholipid) has successfully met its objectives, supporting Acasti's strategy to pursue the U.S. Food and Drug...
Jul 15, 2016 12:26 pm ET
Acasti Announces the Election of its Directors, Change of Fiscal Year End and Other Related Matters Passed at its AGM
Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ: ACST)(TSX VENTURE: APO) of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of hypertriglyceridemia, announced that the nominees listed in its management proxy circular dated June 14, 2016 were elected as directors of Acasti at its Annual and Special Meeting of shareholders held in Montreal, Canada on July 12, 2016 (the "AGM"). The detailed results of the vote for the election of directors are set out below:
Jul 15, 2016 12:26 pm ET
Acasti Announces the Election of its Directors, Change of Fiscal Year End and Other Related Matters Passed at its AGM
Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ:ACST)(TSX VENTURE:APO) of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of hypertriglyceridemia, announced that the nominees listed in its management proxy...
Jul 15, 2016 10:36 am ET
Neptune Announces the Election of its Directors and Change of Fiscal Year End
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (NASDAQ:NEPT)(TSX:NTB), announced that the nominees listed in its management proxy circular dated June 14, 2016 were elected as directors of Neptune at its Annual and...
Jul 15, 2016 10:36 am ET
Neptune Announces the Election of its Directors and Change of Fiscal Year End
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (NASDAQ: NEPT)(TSX: NTB), announced that the nominees listed in its management proxy circular dated June 14, 2016 were elected as directors of Neptune at its Annual and Special Meeting of Shareholders held in Montreal, Canada on July 12, 2016 (the "AGM"). The detailed results of the vote for the election of directors are set out below.
Jul 11, 2016 05:30 pm ET
Acasti Announces First Quarter Results
Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ: ACST)(TSX VENTURE: APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia, announces its operating and financial results for the first quarter of the 2017 fiscal year. All amounts are in Canadian dollars.
Jul 11, 2016 05:30 pm ET
Neptune Announces First Quarter Results
Q1 Financial and Operational Highlights(1):
Jul 11, 2016 05:28 pm ET
Acasti Announces First Quarter Results
Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ:ACST)(TSX VENTURE:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for...
Jul 11, 2016 05:28 pm ET
Neptune Announces First Quarter Results
Q1 Financial and Operational Highlights(1):
Revenues reached $11.3 million, up 270% versus last year
Gross margin on sales rose to 30.5%
Nutraceutical segment generated positive Adjusted...
Jun 30, 2016 10:32 am ET
Neptune to Hold Conference Call to Discuss First Quarter Results for the Period Ended May 31, 2016
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ: NEPT)(TSX: NTB), announces that it will be holding a conference call on July 12, 2016 at 8:00 AM (EST) to discuss its first quarter results for the period ended May 31, 2016.
Jun 30, 2016 10:32 am ET
Neptune to Hold Conference Call to Discuss First Quarter Results for the Period Ended May 31, 2016
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ:NEPT)(TSX:NTB), announces that it will be holding a conference call on July 12, 2016 at 8:00 AM (EST) to discuss its first quarter results for the period ended...
May 25, 2016 05:00 pm ET
Acasti Announces Fourth Quarter and Fiscal Year Results
Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ: ACST)(TSX VENTURE: APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia, announces its operating and financial results for the fourth quarter and fiscal year ended February 29, 2016. All amounts are in Canadian dollars.
May 25, 2016 05:00 pm ET
Neptune Announces Fourth Quarter and Fiscal Year Results
Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT)(TSX: NTB)
May 25, 2016 04:58 pm ET
Neptune Announces Fourth Quarter and Fiscal Year Results
Neptune Technologies & Bioressources Inc. (NASDAQ:NEPT)(TSX:NTB)
Q4 Financial and Operational Highlights (1):
Revenues of $10.0 million, up 161% versus last year
Gross margin on sales rose...
May 25, 2016 04:58 pm ET
Acasti Announces Fourth Quarter and Fiscal Year Results
Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ:ACST)(TSX VENTURE:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for...
May 13, 2016 08:00 am ET
Neptune to Hold Conference Call to Discuss Fourth Quarter and Year-End Results
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ: NEPT)(TSX: NTB), announces that it will be holding a conference call on May 26, 2016 at 8:30 AM (ET) to discuss its results for the fourth quarter and year-end results ended February 29, 2016.
May 13, 2016 07:58 am ET
Neptune to Hold Conference Call to Discuss Fourth Quarter and Year-End Results
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ:NEPT)(TSX:NTB), announces that it will be holding a conference call on May 26, 2016 at 8:30 AM (ET) to discuss its results for the fourth quarter and year-end...
May 12, 2016 08:08 am ET
Jan D'Alvise Appointed President & CEO of Acasti Pharma
Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ:ACST)(TSX VENTURE:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for...
May 12, 2016 08:08 am ET
Jan D'Alvise Appointed President & CEO of Acasti Pharma
Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ: ACST)(TSX VENTURE: APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia, has appointed Ms. Jan D'Alvise as President and Chief Executive Officer effective June 1, 2016.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.